Inquiry Basket
Loading ......
Antibody-drug conjugates (ADCs) represent one of the most innovative and powerful modalities in modern targeted cancer therapy, combining the high specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule chemotherapeutic agents. By precisely delivering cytotoxic payloads to tumor-associated antigens, ADCs significantly minimize off-target toxicity and improve therapeutic selectivity compared to conventional chemotherapy. Among various tumor-targeting ADCs, MUC1-targeted conjugates have attracted extensive research attention due to the broad oncogenic role of MUC1 in multiple solid tumors. The Clivatuzumab MMAE (ADC) is a leading humanized MUC1-targeted ADC candidate, and accurate quantitative detection of this conjugate is essential for preclinical research, pharmacokinetic profiling, and translational studies. The Clivatuzumab MMAE (ADC) ELISA Kit is a specialized immunoassay tool designed to enable precise, reliable, and high-throughput quantification of Humanized Anti-Human MUC1-MMAE ADC [Clivatuzumab-MMAE] in diverse biological samples, supporting the full lifecycle of basic research and preclinical drug development.
FIgure 1.Detection Solution for Humanized Anti-Human MUC1-MMAE ADC.
Clivatuzumab MMAE (ADC) ELISA Kit is a standardized, high-sensitivity enzyme-linked immunosorbent assay kit exclusively optimized for the quantitative analysis of Clivatuzumab-MMAE ADC. Engineered for translational oncology research, this kit delivers consistent and reproducible quantitative data for the target ADC in cell culture supernatants, tissue homogenates, and serum/plasma samples from human and common laboratory animal models. Unlike universal protein detection kits, this product specifically recognizes the intact structure of Humanized Anti-Human MUC1-MMAE ADC, effectively avoiding interference from free MMAE cytotoxic payload, uncoupled Clivatuzumab antibody, and endogenous MUC1 protein in biological samples.
The corresponding target drug, Humanized Anti-Human MUC1-MMAE ADC (Clivatuzumab-MMAE), features a rationally designed dual-component structure. The humanized Clivatuzumab antibody serves as the targeting vector, capable of specific binding to human MUC1 antigen overexpressed on tumor cell surfaces. Linked to the antibody is MMAE (monomethyl auristatin E), a potent antimitotic cytotoxic payload that inhibits tubulin polymerization and induces tumor cell cycle arrest and apoptosis. Benefiting from its high targeting accuracy and strong tumor-killing activity, Clivatuzumab-MMAE has become a critical research candidate for treating MUC1-positive malignancies. This ELISA kit provides indispensable quantitative technical support for evaluating the distribution, enrichment, metabolism, and stability of Clivatuzumab-MMAE in biological systems, laying a solid foundation for mechanism exploration and efficacy verification of MUC1-targeted ADC therapy.
| Key Molecular Targets | Details |
| MUC1 Molecular Target | Mucin 1 (MUC1) is a highly glycosylated transmembrane glycoprotein that is aberrantly overexpressed and structurally modified in a wide range of human solid tumors, including pancreatic cancer, invasive breast cancer, non-small cell lung cancer, ovarian cancer, and gastric cancer. In normal epithelial tissues, MUC1 is lowly expressed and regularly glycosylated, maintaining physiological barrier functions. In tumor tissues, abnormal upregulation and hypoglycosylation of MUC1 expose specific antigen epitopes, which become exclusive recognition sites for Clivatuzumab antibody. The abnormal expression level of MUC1 is positively correlated with tumor proliferation, epithelial-mesenchymal transition, invasion, distant metastasis, and chemotherapy resistance, making it a validated, reliable tumor-specific therapeutic target. |
| MMAE-Mediated Cytotoxic Pathway | The cytotoxic payload MMAE conjugated to Clivatuzumab exerts anti-tumor effects through a classic cell cycle inhibition pathway. After Clivatuzumab-MMAE specifically binds to MUC1 on the tumor cell membrane, the ADC complex is internalized via receptor-mediated endocytosis. Intracellular lysosomal enzymes cleave the linker between the antibody and payload, releasing free MMAE into the cytoplasm. MMAE binds to tubulin, blocks microtubule polymerization and spindle formation, thereby arresting tumor cells in the G2/M phase of the cell cycle and triggering caspase-dependent apoptosis. This targeted cytotoxic pathway ensures that Clivatuzumab-MMAE selectively eliminates MUC1-positive tumor cells without causing widespread damage to normal low-MUC1-expressing tissues. |
| ADC Pharmacological Action Pathway | The overall biological action of Clivatuzumab-MMAE relies on the synergistic effect of targeted recognition and cytotoxic execution. The antibody segment achieves precise tumor targeting, while the MMAE payload completes tumor cell killing. The quantitative detection data provided by the Clivatuzumab MMAE (ADC) ELISA Kit can directly reflect the effective concentration of intact ADC in vivo and in vitro, helping researchers correlate ADC enrichment levels with pathway activation intensity, tumor cell apoptosis rate, and overall therapeutic efficacy. |
Host cell protein (HCP) impurities, which may arise during the manufacturing process of biopharmaceuticals, can contribute to the immunogenicity of therapeutic proteins. In the context of ADCs, HCPs may be present in trace amounts and, when co-administered with the ADC, could potentially act as adjuvants or elicit an immune response that cross-reacts with the therapeutic antibody. Monitoring HCP-related immunogenicity is therefore an important aspect of product characterization and quality control. The Clivatuzumab MMAE (ADC) ELISA Kit is designed with high specificity to ensure accurate quantification of the ADC without interference from HCPs or other matrix components. The assay employs a validated format that minimizes cross-reactivity and non-specific binding, supporting reliable data generation in complex biological matrices.
The Clivatuzumab MMAE (ADC) ELISA Kit has versatile and targeted application values in oncology research, ADC drug development, and translational medicine, covering multiple core research directions:
| Applications | Details |
| Pharmacokinetic (PK) Research | The kit enables dynamic quantitative detection of Clivatuzumab-MMAE concentrations in animal serum and plasma at different administration time points. It supports the analysis of drug absorption, systemic circulation, metabolic rate, and excretion characteristics, providing accurate data for calculating PK parameters such as peak concentration, half-life, and area under the curve, and guiding the optimization of preclinical administration regimens. |
| Preclinical Anti-Tumor Efficacy Evaluation | For MUC1-high tumor xenograft models, the kit quantifies the enrichment of Clivatuzumab-MMAE in tumor tissues and paracancerous normal tissues. It helps researchers verify the tumor-targeting enrichment ability of the ADC, correlate drug accumulation with tumor growth inhibition and metastasis suppression effects, and confirm the in vivo anti-tumor activity of Clivatuzumab-MMAE. |
| ADC Preparation and Quality Control | In laboratory ADC synthesis, coupling purification, and process optimization experiments, the kit can accurately calibrate the concentration of purified Clivatuzumab-MMAE finished products and intermediate samples. It evaluates antibody-payload coupling efficiency and sample purity, standardizing the preparation process and improving the stability and yield of target ADC products. |
1. Clivatuzumab MMAE (ADC) ELISA Kit
This core product is a dedicated quantitative detection kit for MUC1-targeted ADC research. It features high specificity for intact Clivatuzumab-MMAE, excellent sample compatibility, and stable detection performance. Compatible with cell culture supernatants, tissue homogenates, and mammalian serum samples, the kit provides high-repeatability quantitative data for academic research and preclinical drug development, serving as the primary supporting tool for Clivatuzumab-MMAE ADC-related experimental studies.
2. Humanized Anti-Human MUC1-MMAE ADC [Clivatuzumab-MMAE]
As the core detection analyte and research prototype drug, this humanized ADC consists of MUC1-specific humanized Clivatuzumab antibody and MMAE cytotoxic payload. With high tumor targeting specificity and potent anti-tumor activity, it is widely used in preclinical research on MUC1-positive solid tumors. It serves as the key research object for efficacy verification, mechanism exploration, and pharmacokinetic study, matching perfectly with the supporting detection function of the Clivatuzumab MMAE (ADC) ELISA Kit.
Clivatuzumab-MMAE, as a promising humanized MUC1-targeted ADC, exerts precise and efficient anti-tumor effects by targeting aberrantly expressed MUC1 on tumor cells and releasing MMAE to block tumor cell proliferation and induce apoptosis. The Clivatuzumab MMAE (ADC) ELISA Kit is a professional and exclusive detection tool developed for this targeted ADC drug, filling the gap in specific quantitative detection of Clivatuzumab-MMAE in complex biological samples. With reliable detection accuracy, wide sample adaptability, and standardized operation system, the kit fully supports pharmacokinetic analysis, preclinical efficacy evaluation, drug quality control, and basic mechanistic research of Clivatuzumab-MMAE.
The combination of Humanized Anti-Human MUC1-MMAE ADC and its matched ELISA detection kit forms a complete research system for MUC1-targeted ADC therapy. It provides strong technical support for in-depth exploration of the clinical transformation potential of MUC1-targeted anti-tumor drugs, accelerates the basic research and industrialization process of Clivatuzumab-MMAE, and offers new research ideas and technical references for the targeted treatment of MUC1-positive malignant tumors.
| Cat. No. | Product Name | Species Reactivity | Application | Detection Method | BusinessCode | RefAuthor | Size | |
| DEIA-JY25388 | Clivatuzumab MMAE (ADC) ELISA Kit | Human | Quantitative | sELISA | CD-E-O | 96T | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | BusinessCode | RefAuthor | Size | |
| MUC1 | DMAB-CLS25230 | Humanized Anti-Human MUC1-MMAE ADC [Clivatuzumab-MMAE] | Human | IgG | Reference Antibody | CD-Ab-CM | 10 mg | Inquiry |
Loading ......
